Dr. Phil Bonomi, from Rush University, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.

[powerpress]

Dr. Leighl continued her presentation on "Highlights in Lung Cancer, 2012" with a discussion of the challenges that many patients with squamous NSCLC face, typically not having a cancer with a "driver mutation" like an EGFR mutation or an ALK rearrangement.

Dr. Heather Wakelee from Stanford University presents her view on the most promising emerging targeted therapies and pathways for treating lung cancer in the coming years.

[powerpress]

Dr. Greg Riely, Memorial Sloan-Kettering, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.

[powerpress]

Drs. Ross Camidge and Corey Langer offer their perspectives on the most encouraging emerging targets that could become valuable additions to our lung cancer treatment menu in the next several years.

[powerpress]

Dr. Rosalyn Juergens, McMaster Unievrsity, offers her perspective on the treatments emerging as showing the greatest promise as effective novel therapies for patients with lung cancer.

[powerpress]

Dr. David Spigel from Sarah Cannon Cancer Center offers his perspective on the agents he feels most likely to become clinical tools against lung cancer over the next few years.

[powerpress]

Here's a video I just did on the disappointing results of the START trial with Stimuvax, an immunotherapy that was very promising but didn't actually pan out, but why might that have happened, and what does it mean for the future, with other clinical trials with prominent immune-based treatments that have also looked promising in lung cancer?

[powerpress]

What do you think? Are you optimistic about Lucanix and the MAGE-A3 trial?

While the main story coming out of the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology focused on the relatively disappointing results of the PointBreak trial, one positive trial received quite a bit of attention.  Dr.

Continuing with our post-ASCO highlights presentation, we now turn to Dr. Joel Neal, Assistant Professor at Stanford Cancer Center, who covered several targeted therapy options that are still working their way through investigational work.